Supriya Lifescience Ltd., a leading name in the global pharmaceutical industry, has achieved two significant milestones that underline its commitment to innovation and affordable healthcare. The company has become the first Indian pharmaceutical firm to receive approval for Esketamine Hydrochloride from Brazil’s health authority, ANVISA (Agência Nacional de Vigilância Sanitária). Additionally, it has filed a groundbreaking patent for a low-cost manufacturing process of Atorvastatin, a widely used drug for managing cholesterol and preventing cardiovascular diseases.
First Indian Nod for Esketamine Hydrochloride
Esketamine Hydrochloride, a cutting-edge drug used in the treatment of mental health conditions, is poised to revolutionize access to mental healthcare in Brazil and the broader Latin American (LATAM) region. With the ANVISA approval, Supriya Lifescience strengthens its presence in the LATAM market, where the demand for innovative and affordable medicines is rapidly growing.
This landmark regulatory approval enables the company to offer high-quality and advanced therapies to a region in dire need of effective solutions for mental health challenges. By becoming the first company in Brazil to receive this approval, Supriya Lifescience is set to pave the way for expanded healthcare options in LATAM.
Low-Cost Breakthrough for Atorvastatin Manufacturing
In another remarkable achievement, Supriya Lifescience has filed a patent for a cost-effective and innovative process to manufacture Atorvastatin, one of the world’s most prescribed drugs for controlling cholesterol and reducing the risk of cardiovascular disease. This new technique not only reduces production costs but also improves the drug’s overall efficacy, making it more accessible to patients worldwide.
Atorvastatin plays a critical role in global healthcare, and Supriya’s innovation aligns with its mission to improve affordability and expand access to essential medications.
Leadership Insights
Dr. Satish Wagh, Executive Chairman and Whole-Time Director of Supriya Lifescience Ltd., expressed pride in the company’s achievements.
“Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our innovation in the synthesis of Atorvastatin. Our global presence is strengthened by the CADIFA approval, which allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in crucial international markets, starting with Brazil.”
Strengthening Global Presence
With the CADIFA approval and a robust patent portfolio, Supriya Lifescience is well-positioned to capitalize on the rapidly growing LATAM market. The company’s focus on regulatory compliance, cutting-edge innovation, and affordability underscores its dedication to delivering high-quality healthcare solutions globally.
About Supriya Lifescience Ltd.
Founded in 1987, Supriya Lifescience Ltd. is a globally renowned manufacturer of active pharmaceutical ingredients (APIs). Headquartered in Mumbai, India, the company operates a state-of-the-art facility in Khed, Ratnagiri, certified by leading global regulatory bodies including the US FDA, Health Canada, ANVISA, EMA, and TGA.
Supported by advanced R&D capabilities, Supriya Lifescience holds eight active CEPs and fourteen active USDMFs, producing APIs and intermediates for both innovators and generic pharmaceutical companies. Guided by ethical principles and stringent EHS standards, the company remains at the forefront of delivering high-quality healthcare solutions worldwide.